Phitech (Decision/Risk Analysis) key facts
as of Oct 2026- Developer of genomic algorithms designed to extract critical information for diagnostic decision-making.
- Phitech (Decision/Risk Analysis) is valued at approximately $5.6M as of Oct 2026 (last reported valuation).
- It has raised $3.5M; the latest was Later Stage VC ($2.4M) in Apr 2026.
- Notable investors include Alchemist Accelerator, IstCapital, Eksim Venture, Adem Akkaya, Ahmet Atasoy — 30 tracked in total.
- Status: Privately Held (backing).
Phitech (Decision/Risk Analysis)'s last reported valuation, Feb 2024. Nothing priced has surfaced since.
- ·The complete investor list: 30 names
- ·Watch Phitech (Decision/Risk Analysis): the Monday email on marks, rounds and moves
Phitech (Decision/Risk Analysis) funding rounds
No funding rounds for Phitech (Decision/Risk Analysis) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Phitech (Decision/Risk Analysis)
30+Phitech (Decision/Risk Analysis) valuation
Phitech (Decision/Risk Analysis)'s last reported valuation was $5.6 million in Feb 2024. No priced round, secondary trade or fund mark has surfaced since.
Phitech (Decision/Risk Analysis) investors
30 investors are on record for Phitech (Decision/Risk Analysis), including Alchemist Accelerator, IstCapital, Eksim Venture and Adem Akkaya.
About Phitech (Decision/Risk Analysis)
Developer of genomic algorithms designed to extract critical information for diagnostic decision-making. The company offers translation of genome-wide molecular data such as genomics, transcriptomics, epigenomics, and microbiomics into biotechnology systems, enabling healthcare professionals to make diagnostic decision-making and use in precision medicine.
- Sector
- Healthcare
- HQ
- Kocaeli, Turkey
- Employees
- 22
- Website
- phitech.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.